FDA approves Qelbree for attention-deficit hyperactivity disorder in pediatric patients – Supernus Pharmaceuticals
Supernus Pharmaceuticals announced that the FDA approved Qelbree (viloxazine extended-release capsules) for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age…. read more.
